Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis
- 31 August 2003
- journal article
- clinical trial
- Published by Elsevier BV in Annals of Allergy, Asthma & Immunology
- Vol. 91 (2), 160-167
- https://doi.org/10.1016/s1081-1206(10)62171-0
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Effect of Omalizumab on Symptoms of Seasonal Allergic RhinitisA Randomized Controlled TrialJAMA, 2001
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJournal of Allergy and Clinical Immunology, 2001
- Allergic rhinitis: Definition, epidemiology, pathophysiology, detection, and diagnosisJournal of Allergy and Clinical Immunology, 2001
- The work impact of asthma and rhinitisJournal of Clinical Epidemiology, 2001
- The health economics of asthma and rhinitis. I. Assessing the economic impactJournal of Allergy and Clinical Immunology, 2001
- Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen–induced seasonal allergic rhinitisJournal of Allergy and Clinical Immunology, 2000
- Patient and physician perspectives on the impact and management of perennial and seasonal allergic rhinitisClinical Otolaryngology, 2000
- Diagnosis and Management of Rhinitis: Complete Guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and ImmunologyAnnals of Allergy, Asthma & Immunology, 1998
- Impact of upper respiratory allergic diseases on quality of life.Journal of Allergy and Clinical Immunology, 1998
- Learning Impairment and Allergic RhinitisAllergy and Asthma Proceedings, 1996